ALBERTA PRECISION LABORATORIES
Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	4 May 2026
TO:	All Zones: All Healthcare Providers
FROM:	Clinical Biochemistry, Alberta Precision Laboratories (APL)
RE:	**Temporary Changes to Anti-Cardiolipin IgG Antibody Testing and Reporting**

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- **Effective immediately**, there is a current delay and change in test reporting for some *Anti-Cardiolipin IgG Antibody* results.

Background

- The University of Alberta Hospital (UAH) in Edmonton and the Diagnostic Scientific Centre (DSC) in Calgary are unable to report Anti-Cardiolipin IgG Antibody results ≥1.6 due to manufacturer reagent issues.
- The estimated time for the manufacturer to provide new reagent is at least 2 months.

How this will impact you

- No change to collection and ordering for Anti-Cardiolipin Antibody (IgG or IgM).
- UAH and DSC will continue to run and report Anti-Cardiolipin IgG Antibody results <1.6.
- Anti-Cardiolipin IgG Antibody blood samples with results ≥1.6 will be referred to MitogenDx for testing on an alternative method (ELISA).
- Refer to the Appendix for reporting changes.
- Patients having serial monitoring (initial and repeat tests) at the time of transition may need a new baseline for comparison.
- Test result reporting may be delayed beyond stated turnaround times.
- Mitogen results will be reported on Connect Care and Netcare.

Action Required

- Continue routine ordering practice.
- Be aware that approximately 10% of samples are expected to be ≥1.6 and referred to MitogenDx
- If Anti-Cardiolipin IgG Antibody results are required urgently, contact the clinical biochemist on call.
- For Edmonton, North and Central Zone: University of Alberta Hospital switchboard at 780-407-8822.
- For Calgary and South Zone: Regional On Call Application

Questions/Concerns

- Dr. Kareena Schnabl, Clinical Biochemist, Edmonton, 780-407-3186, Kareena.Schnabl@aplabs.ca
- Dr. Qian Wang, Clinical Biochemist, Calgary, 403-770-3219, Qian.Wang@aplabs.ca
- Shelley McCallum, MitogenDx, 403-800-8851, lab@mitogendx.com

Approved by

- Dr. Allison Venner, Section Chief, Clinical Biochemistry, South Sector, APL
- Dr. Carolyn O'Hara, Interim Chief Medical Laboratory Officer, APL

Appendix

Table: APL and MitogenDx Referral Lab Reporting for Anti-Cardiolipin IgG Antibody

	APL (UAH and DSC)	**Referral Lab MitogenDx**
Method (Units)	Multiplex Bead Immunoassay (Bioplex) (GPL - U/mL)	ELISA (GPL)
Reference Interval	Negative <20 Low Positive 20 - 40 Moderate Positive 40 - 80 High Positive >80	Negative <15 Indeterminate ≤15 - <20 Low Positive ≥20 - ≤80 High Positive >80
Reporting Comments	**Negative** – Fulfills the 99th percentile cutoff as described by the 2006 Sydney criteria. J. Thromb. Haemost. 2006; 4:295-306. **Positive** results (>=20 GPL-U/mL) are defined as >99th percentile cutoff and are associated with Anti-Phospholipid Syndrome when measured on two or more occasions at least 12 weeks, but not more than 5 years apart, as defined by the 2006 Sydney criteria (J. Thromb. Haemost. 2006; 4:295-306)	Refer to “Anti-Cardiolipin, IGG & IGM”. Note only IgG will be performed and reported by MitogenDx.